Evidence map›Paper›PMID 33802446›Full record

ReviewCancers2021

Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases.

Alessandra Rigamonti, Friedrich Feuerhake, Matteo Donadon, Massimo Locati, Federica Marchesi

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Alessandra RigamontiDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Friedrich FeuerhakeInstitute of Pathology, Hannover Medical School, D-30625 Hannover, Germany.ORCID 0000-0002-1234-982X
Matteo DonadonDepartment of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.ORCID 0000-0003-0296-7648
Massimo LocatiDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Federica MarchesiDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.ORCID 0000-0002-7212-5721
University of Milan · ITHumanitas University · ITMedizinische Hochschule Hannover · DE

Funding

Associazione Italiana Ricerca sul Cancro AIRC 5x1000 IG-21147
6 · The paper itself

Abstract

Prognostic studies are increasingly providing new tools to stratify colo-rectal liver metastasis patients into clinical subgroups, with remarkable implications in terms of clinical management and therapeutic choice. Here, the strengths and hurdles of current prognostic tools in colo-rectal liver metastasis are discussed. Alongside more classic histopathological parameters, which capture features related to the tumor component, such as tumor invasion, tumor growth pattern and regression score, we will discuss immune mediators, which are starting to be considered important features. Their objective quantification has shown significant results in prognostication studies, with most of the work focused on adaptive immune cells, namely T cells. As for macrophages, they are only starting to be appreciated and we will present recent advances in evaluation of macrophage morphological features. Deeper knowledge acquired by multiparametric analyses is rapidly uncovering the variety of immune players that should be assessed. The future projection is to implement deep-learning histopathological tools and to integrate histopathological and immune metrics in multiparametric scores, with the ultimate objective to achieve a deeper resolution of the tumor features and their relevance for colo-rectal liver metastasis.

Indexed as

colo-rectal liver metastasisgrowth patternsmacrophagesprognosistumor regression score

Identifiers

PMID33802446
PMCPMC7959473
OpenAlexW3135301319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.